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Risk of myocardial infarction in patients with HIV infection
exposed to specific individual antiretroviral drugs from the 3
major drug classes: the data collection on adverse events of
anti-HIV drugs (D:A:D) study
Abstract
BACKGROUND. The risk of myocardial infarction (MI) in patients with human immunodeficiency
virus (HIV) infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events
of Anti-HIV Drugs (D:A:D) study. METHODS. Poisson regression models were adjusted for
cardiovascular risk factors, cohort, calendar year, and use of other antiretroviral drugs and assessed the
association between MI risk and cumulative (per year) or recent (current or in the past 6 months) use of
antiretroviral drugs, with >30,000 person-years of exposure. RESULTS. Over 178,835 person-years,
580 patients developed MI. There were no associations between use of tenofovir, zalcitabine,
zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine was
associated with an increased risk of MI. No association was found between MI risk and cumulative
exposure to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and
lopinavir-ritonavir was associated with an increased risk of MI (relative rate [RR] per year, 1.12 and
1.13, respectively). These increased risks were attenuated slightly (RR per year, 1.08 [95% confidence
interval {CI}, 1.02-1.14] and 1.09 [95% CI, 1.01-1.17], respectively) after adjustment for lipids but
were not altered further after adjustment for other metabolic parameters. CONCLUSIONS. Of the drugs
considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were associated with a
significantly increased risk of MI. As with any observational study, our findings must be interpreted
with caution (given the potential for confounding) and in the context of the benefits that these drugs
provide.
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for Sexual Health and HIV Research, University College London, London, United Kingdom; 4Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Zurich, Zurich, Switzerland; 5HIV Monitoring Foundation, Academic Medical Center, Amsterdam, the Netherlands; 6Columbia
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(See the editorial commentary by Aberg and Ribaudo, on pages 315–17.)
Background. The risk of myocardial infarction (MI) in patients with human immunodeficiency virus (HIV)
infection has been assessed in 13 anti-HIV drugs in the Data Collection on Adverse Events of Anti-HIV Drugs
(D:A:D) study.
Methods. Poisson regression models were adjusted for cardiovascular risk factors, cohort, calendar year, and
use of other antiretroviral drugs and assessed the association between MI risk and cumulative (per year) or recent
(current or in the past 6 months) use of antiretroviral drugs, with 130,000 person-years of exposure.
Results. Over 178,835 person-years, 580 patients developed MI. There were no associations between use of
tenofovir, zalcitabine, zidovudine, stavudine, or lamivudine and MI risk. Recent exposure to abacavir or didanosine
was associated with an increased risk of MI. No association was found between MI risk and cumulative exposure
to nevirapine, efavirenz, nelfinavir, or saquinavir. Cumulative exposure to indinavir and lopinavir-ritonavir was
associated with an increased risk of MI (relative rate [RR] per year, 1.12 and 1.13, respectively). These increased
risks were attenuated slightly (RR per year, 1.08 [95% confidence interval {CI}, 1.02–1.14] and 1.09 [95% CI,
1.01–1.17], respectively) after adjustment for lipids but were not altered further after adjustment for other metabolic
parameters.
Conclusions. Of the drugs considered, only indinavir, lopinavir-ritonavir, didanosine, and abacavir were as-
sociated with a significantly increased risk of MI. As with any observational study, our findings must be interpreted
with caution (given the potential for confounding) and in the context of the benefits that these drugs provide.
The prevalence of traditional cardiovascular disease
(CVD) risk factors, such as smoking and dyslipidemia,
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is generally higher in the human immunodeficiency
virus (HIV)–infected population, compared with the
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general population [1], although the situation has improved
somewhat over the past few years [2, 3]. We have previously
demonstrated an increased risk of myocardial infarction (MI)
among patients exposed to combination antiretroviral therapy
(CART) for longer periods [4], particularly those exposed to
protease inhibitors (PIs) [5] and those recently exposed to the
nucleoside reverse-transcriptase inhibitors (NRTIs) abacavir
and didanosine [6]. In contrast, no association was found be-
tween the risk of MI and exposure to nonnucleoside reverse-
transcriptase inhibitors (NNRTIs) [5] or any of the other NRTIs
studied [6].
Several drugs from the PI class have been reported to cause
dyslipidemia, hyperglycemia, and overt diabetes mellitus [7–
12], and clinicians deciding which particular PI to prescribe
often take this into account. Because individual drugs within
the PI class differ in their propensity to cause metabolic dis-
turbances, it is important to identify the contribution of each
PI to the risk of MI. Drugs from the NNRTI class have also
been associated with the development of dyslipidemia [13, 14].
The extent to which either of the 2 commonly used NNRTIs,
efavirenz and nevirapine, is associated with the risk of MI re-
mains to be determined. We now have sufficient follow-up time
among individuals exposed to several specific PIs and NNRTIs
to robustly describe the associations between these drugs and
the risk of MI. Furthermore, since the publication of our find-
ings linking recent use of abacavir and didanosine to an in-
creased risk of MI [6], we have also accrued sufficient follow-
up time on a more recently approved NRTI, tenofovir, to permit
an analysis of the association between this drug and the risk
of MI.
METHODS
The Data Collection on Adverse Events of Anti-HIV Drugs (D:
A:D) study is an international collaboration of 11 cohorts that
follows 33,308 HIV type 1–infected patients at 212 clinics in
Europe, the United States, and Australia. For the purpose of
our analyses, an individual was defined as having hypertension
if the individual had a systolic blood pressure of 1140 mm Hg,
had a diastolic blood pressure of 190 mm Hg, or was receiving
antihypertensive medication or angiotensin-converting enzyme
inhibitors. Dyslipidemia was considered present if the individ-
ual had a total cholesterol level of 6.2 mmol/L, had a high-
density lipoprotein (HDL) cholesterol level of 0.9 mmol/L,
had a triglyceride level of 2.3 mmol/L, or was receiving lipid-
lowering drugs. Ten-year predicted risk of coronary heart dis-
ease was determined using the Framingham equation [15].
Outcomes. All incident cases of MI during follow-up were
reported to the study coordinating office for validation and
coding. Reported MIs were classified as definite, possible, or
unclassifiable, according to criteria applied in the World Health
Organization Monitoring Trends and Determinants in Cardio-
vascular Disease (MONICA) study [16] and independently of
knowledge of a patient’s antiretroviral treatment history. Other
validated outcomes included strokes (definitive or possible),
invasive cardiovascular procedures (coronary artery angioplasty
or bypass, or carotid endarterectomy), diabetes mellitus, and
death.
Statistical analysis. Seven NRTIs (zidovudine, stavudine,
didanosine, zalcitabine, lamivudine, abacavir, and tenofovir), 4
PIs (indinavir, nelfinavir, lopinavir-ritonavir, and saquinavir),
and 2 NNRTIs (efavirenz and nevirapine) reached the prespeci-
fied follow-up requirements: an exposure time of at least 30,000
person-years of follow-up (PYFU) with a median individual
postexposure follow-up of 11 year. In order to meet these
thresholds, we combined the follow-up of patients exposed to
indinavir with that of patients without concomitant ritonavir
use; similarly, we combined the follow-up from patients exposed
to saquinavir with that of patients without ritonavir. Thus, our
main analyses describe associations between any exposure to
these 2 drugs (saquinavir and indinavir) and the development
of MI, regardless of concomitant ritonavir use. However, as a
sensitivity analysis, we also explored the separate associations of
each drug with MI risk when used with or without ritonavir; of
note, these analyses were based on !30,000 PYFU and therefore
should be interpreted with caution.
Determination of the risk of MI. Full details of the ana-
lytical approach have been described elsewhere [4, 17]. Indi-
viduals were followed up prospectively from enrolment in D:
A:D to the date of the first occurrence of MI during prospective
follow-up, the date of death, 6 months after a patient’s last
clinic visit, or 1 February 2008, whichever occurred first. As in
previous analyses, each person’s follow-up was divided into a
series of consecutive 1-month periods, and a patient’s cumu-
lative and current exposure to each antiretroviral drug at the
start of each period was determined (including exposure to
treatment before enrollment in D:A:D). Each person’s covariate
data were also updated at the start of each month, permitting
a time-varying analysis. Any follow-up and events that occurred
in that patient-month were then attributed to the characteristics
of the patient at the start of that month.
Relationships between exposure to each drug and MI.
Poisson regression models (GENMOD procedure in SAS soft-
ware, version 9.1; SAS) were used to quantify the relationship
between exposure to each drug and the risk of MI. All P values
quoted are 2-sided, and results for which were consid-P ! .05
ered statistically significant. All regression models were also
adjusted for patient demographic characteristics (age, sex, HIV
transmission group, and ethnicity), calendar year, clinical co-
hort, cardiovascular risk factors that are unlikely to be asso-
ciated with use of CART (smoking status, family history of
CVD, previous cardiovascular event [including previous MIs],
 at Zentralbibliothek on January 16, 2011
jid.oxfordjournals.org
D
ow
nloaded from
 
320 • JID 2010:201 (1 February) • Worm et al
and body mass index), and exposure to each of the other an-
tiretroviral drugs that was in use over the study period (the 13
drugs listed above, as well as ritonavir when used as a single
PI, amprenavir, and atazanavir, which were all also used in
smaller numbers of patients). Where numbers were sufficiently
large, specific categories were generated for missing data to
ensure that all individuals and observed events were included
in the analyses. An approximate test of heterogeneity, based on
the difference between the log-likelihoods from this main
model (which included separate covariates representing ex-
posure to each of the PIs) and a model that included only a
covariate for exposure to PIs as a class, was performed to assess
whether there was evidence that at least 1 PI drug had an
association with MI that was different from the others.
The models described above did not adjust for factors that
could lie on the causal pathway between receipt of each drug
and the development of MI (eg, lipids and elevated blood pres-
sure). Thus, we explored whether any effects could be mediated
through changes in the levels of other risk factors for MI that
may be modified by CART, including lipids (total cholesterol,
HDL cholesterol, and triglyceride levels [log2-transformed]),
systolic and diastolic blood pressure, glucose level, the presence
of diabetes mellitus, physician-defined lipodystrophy, and the
use of lipid-lowering therapy or antihypertensive medication.
This was achieved by the incorporation of the latest measure-
ments of these variables as time-updated covariates. All lipid
measurements were included, regardless of fasting status. We
also considered whether any effects could be explained by dif-
ferent responses of HIV RNA level or CD4+ cell count to CART
in patients receiving the different drugs by incorporating the
latest value for these variables as time-updated continuous
covariates.
In our analyses, we assume that the risk of MI associated
with exposure to each PI is persistent and does not diminish
after discontinuation of that drug. Thus, when a patient dis-
continues a PI, any follow-up and events continue to be at-
tributed to the level of exposure to the PI at the time of dis-
continuation. However, if patients at risk of CVD who are
receiving drugs thought to be associated with an increased CVD
risk are selectively switched away from these drugs, our ap-
proach may underestimate the associations of interest. We in-
vestigated this possibility by reclassifying any follow-up and
events that occurred 16 months after discontinuation of each
PI in such a way that they were no longer attributed to the
previous drug.
RESULTS
Characteristics of patients with MI. The 33,308 patients con-
tributed a total of 178,835 PYFU to the analysis (median per
person, 5.8 PYFU [interquartile range {IQR}, 3.9–7.5 PYFU]),
over which time 580 patients experienced an MI (event rate,
3.2 events per 1000 PYFU [95% confidence interval {CI}, 3.0–
3.5 events per 1000 PYFU]). Those experiencing an MI were
mostly men (90.7%), white (59.5%), and infected with HIV
through sex with men (57.4%) and had a median age at the
time of MI of 49 years; cardiovascular risk profiles of the men
experiencing an MI, as well as those of all other patients, are
shown in Table 1. Of those who experienced an MI, 573 (98.8%)
had been exposed to antiretroviral therapy, 114 of whom were
not receiving therapy at the time of their MI. The median latest
CD4+ cell count before the diagnosis of MI and the nadir CD4+
cell count were 440 cells/mL (IQR, 292–628 cells/mL) and 128
cells/mL (IQR, 50–240 cells/mL), respectively. For over half (302
[52.1%]) of the 580 patients who developed MI, the latest HIV
RNA level was !50 copies/mL before the MI. Among all patients
experiencing an MI, the 10-year predicted risk of coronary heart
disease was known to be high (ie, 120%) in 18.1% and mod-
erate (ie, 10%–20%) in 30.3%; in contrast, only 4.2% and
14.5% of those not experiencing an MI fell into the high- and
moderate-risk categories, respectively.
The cardiovascular risk profiles of patients who had ever
been exposed to any of the drugs are shown in Table 2 for each
drug. Although some differences were apparent in the char-
acteristics of patients exposed to each of the drugs, these dif-
ferences were not large. Of note, the characteristics of patients
exposed to abacavir and tenofovir were similar.
Risk of MI according to exposure to individual drugs.
Incidence rates of MI according to cumulative exposure are
shown in Figure 1 for the 4 PIs and 2 NNRTIs and in Figure
2 for the 7 NRTIs. Among the PIs, after adjustments (Table 3),
there was a significantly increased risk of MI in patients with
longer exposure to indinavir (relative rate [RR] per additional
year, 1.12 [95% CI, 1.07–1.18]) or lopinavir-ritonavir (RR, 1.13
[95% CI, 1.05–1.21]), but there were no significant associations
between MI risk and longer exposure to either nelfinavir (RR,
1.04 [95% CI, 0.98–1.11]) or saquinavir (RR, 1.04 [95% CI,
0.98–1.11]) ( for approximate test of heterogeneity be-Pp .03
tween drugs from the PI class). In the sensitivity analyses, we
also considered whether recent exposure to each PI was a stron-
ger predictor of MI risk than was cumulative exposure—this
was not the case. There were no significant associations between
the development of MI and cumulative exposure to either efa-
virenz (RR, 1.02 [95% CI, 0.96–1.08]) or nevirapine (RR, 0.97
[95% CI, 0.92–1.03]). Of the NRTIs, the only significant as-
sociation between MI risk and cumulative exposure was with
abacavir (RR, 1.07 [95% CI, 1.00–1.14]); recent exposure to
abacavir (RR, 1.70 [95% CI, 1.17–2.47]) or didanosine (RR,
1.41 [95% CI, 1.09–1.82]) were both associated with an in-
creased risk of MI. There were no significant associations be-
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Table 1. Cardiovascular Risk Profiles
Characteristic
No. (%) of patients
With MI
( )np 580
Without MI
( )np 32,728
Male sex 526 (90.7) 24,143 (73.8)
Age, median years (IQR) 49 (43–65) 44 (38–50)
BMI 126 109 (18.8) 5675 (17.3)
Current smoker 260 (44.8) 9386 (28.7)
Ex-smoker 173 (29.8) 9850 (30.1)
Cardiovascular disease
In own history 116 (20.0) 823 (2.5)
In family history 79 (13.6) 2707 (8.3)
Diabetes mellitus 96 (16.6) 1730 (5.3)
Hypertension
Using antihypertensive medication 198 (34.1) 3602 (11.0)
Any hypertension 252 (43.5) 6290 (19.2)
Latest lipid levels
Total cholesterol level, median mmol/L (IQR) 5.7 (4.7–6.6) 4.8 (4.1–5.6)
HDL cholesterol level, median mmol/L (IQR) 1.1 (0.9–1.3) 1.2 (1.0–1.5)
Triglyceride level, median mmol/L (IQR) 2.2 (1.5–3.9) 1.6 (1.0–2.4)
Using lipid-lowering medication 209 (36.0) 4084 (12.5)
Any dyslipidemia 434 (74.8) 14,506 (44.3)
Lipodystrophy 243 (41.9) 8566 (26.2)
Predicted 10-year CHD riska
Low (!10%) 152 (26.2) 17,509 (53.5)
Moderate (10%–20%) 176 (30.3) 4740 (14.5)
High (120%) 105 (18.1) 1371 (4.2)
Not known 147 (25.3) 9108 (27.8)
Categorization of MIb
Definitive 371 (64.0) NA
Possible 132 (22.8) NA
Unclassifiable 77 (13.3) NA
Fatal MI event 148 (25.5) NA
NOTE. Data are no. (%) of patients, unless otherwise indicated. Risk profiles for patients expe-
riencing a myocardial infarction (MI) were calculated at the time of the first MI experienced during
follow-up; those for patients not experiencing an MI were calculated at the time of the last D:A:D
follow-up visit. BMI, body mass index (calculated as mass in kilograms divided by the square of height
in meters); CHD, coronary heart disease; HDL, high-density lipoprotein; IQR, interquartile range; NA,
not applicable.
a Predicted 10-year CHD risk based on the Framingham equation (patients with a previous cardio-
vascular event were assumed to have high [120%] risk).
b MIs categorized according to the Dundee classification.
tween MI risk and recent exposure to any of the other NRTIs;
in particular, there was no association between the risk of MI
and either cumulative (RR per year, 1.04 [95% CI, 0.91–1.18])
or recent (RR, 1.14 [95% CI, 0.85–1.53]) exposure to tenofovir.
Table 3 shows the associations between MI risk and recent
use of abacavir and didanosine, as well as those between MI
risk and cumulative exposure to abacavir, lopinavir-ritonavir,
and indinavir after adjustment. Adjustment for these mea-
surements had only minimal effect on the estimates. Further
adjustment for latest CD4+ cell count and HIV RNA level also
did not substantially modify any of the estimates.
Sensitivity analysis. The RR per year of exposure to in-
dinavir when received with ritonavir (22,186 PYFU among in-
dividuals exposed to this combination) was 1.18 (95% CI, 1.07–
1.30); that for individuals exposed to indinavir without con-
comitant exposure to ritonavir (57,961 PYFU) was 1.11 (95%
CI, 1.05–1.18). Similarly, the RR per year of exposure to sa-
quinavir was 1.06 (95% CI, 0.97–1.14; 24,727 PYFU) when
received concomitantly with ritonavir, but it was 1.07 (95% CI,
0.97–1.20; 26,145 PYFU) when received without ritonavir.
When we reran the analyses in such a way that patient follow-
up and events occurring 16 months after discontinuation of
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Figure 1. Incidence rates of myocardial infarction according to cumulative exposure to the 4 protease inhibitors (A–D) and 2 nonnucleoside reverse-
transcriptase inhibitors (E, F) in this study. The error bars indicate the 95% confidence interval. PYFU, person-years of follow-up.
each PI no longer contributed to the risk associated with those
drugs, the estimates from the model were modified only slightly
(eg, the RR associated with each year of exposure to lopinavir-
ritonavir decreased from 1.13 to 1.12, whereas that for exposure
to indinavir increased from 1.12 to 1.14).
DISCUSSION
We examined the association between exposure to 13 antiret-
roviral drugs from the 3 main drug classes and the risk of MI.
Of the drugs examined, cumulative exposure to indinavir (with
or without ritonavir boosting), lopinavir-ritonavir, and aba-
cavir, as well as recent exposure to abacavir and, to a lesser
extent, didanosine, were each associated with an increased risk
of MI. No increased risk of MI was noted with use of other
NRTIs, including tenofovir, or with use of efavirenz or nevi-
rapine. As in previous analyses, the associations between MI
risk and either lopinavir-ritonavir or indinavir did not appear
to be fully explained by an increased risk of dyslipidemia in
patients with longer exposure to these drugs.
Of interest, the associations reported for the 2 PIs (12% per
year for indinavir and 13% per year for lopinavir-ritonavir) are
both slightly lower than that previously reported from the D:
A:D study for the PI drug class as a whole (16% per additional
year) [5]. Our previously reported findings were not, however,
adjusted for exposure to NRTIs, either as a class or as individual
drugs. There are differences between the individual drugs from
the PI class in their propensity to cause metabolic disturbances
[8–15]. In particular, lopinavir-ritonavir can cause elevated tri-
glyceride levels [9, 18, 19], whereas indinavir (particularly when
used with concomitant ritonavir) and saquinavir are both as-
sociated with the development of other lipid perturbations [20,
21]. Two recent trials showed that ritonavir-boosted saquinavir
was associated with a better lipid profile than was lopinavir-
ritonavir [22, 23], although the significant difference between
the 2 drugs in the ratio between fasting total cholesterol level
and HDL level was not detected at 48 weeks after randomization
[23]. The associations that we found between MI risk and
exposure to saquinavir were similarly not affected by concom-
itant exposure to ritonavir. Furthermore, although the reported
associations between MI risk and exposure to indinavir and
lopinavir-ritonavir were reduced slightly after adjustment for
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Figure 2. Incidence rates of myocardial infarction according to cumulative exposure to the 7 nucleoside reverse-transcriptase inhibitors in this study.
The error bars indicate the 95% confidence interval. PYFU, person-years of follow-up.
changes in lipids, these reductions were small (from 1.12 to
1.08 for indinavir and from 1.13 to 1.09 for lopinavir-ritonavir).
Taken together, our results would suggest that the increased
risk of MI found in patients receiving these PIs may not solely
be a consequence of the dyslipidemia caused by these drugs.
Other possible explanations for the increased risk of MI as-
sociated with exposure to some of the PIs may include increased
inflammation and coagulation. A recent article reported that
the PI drug class was associated with increased levels of fibrin-
ogen [24]. Of interest, in that study the levels of fibrinogen
were higher in patients receiving PIs (particularly lopinavir-
ritonavir) compared with those receiving NNRTIs.
Although the risk associated with each additional year of
exposure to indinavir and lopinavir-ritonavir appears to be
modest, the extent of exposure to each drug must be taken
into account when assessing individual risk. Our preliminary
analyses (Figure 1) demonstrated that the risk of MI increases
with longer exposure to each drug, unlike the MI risk associated
with NRTIs; because patients are seldom treated with PIs for
only a single year, our estimates will translate into a clinically
relevant risk when considered over a longer period of time. For
example, our estimates would suggest that 5 years of exposure
to lopinavir-ritonavir would be associated with an increased
risk of MI of 84%, an excess risk that is roughly equivalent to
that associated with aging by 10 years (which is associated with
an 80% increased risk of MI in the same analysis).
Newer drugs within the PI class, in particular atazanavir,
have been reported to cause fewer lipid perturbations [25, 26]
than does lopinavir-ritonavir and has been reported to cause
dyslipidemia to an extent similar to that caused by ritonavir-
boosted saquinavir [26, 27]. Additional follow-up will allow us
to explore the risk of MI associated with atazanavir use, as well
as with use of more recently introduced PIs, such as darunavir.
Individual drugs from the NRTIs. As previously reported,
we found that recent exposure to abacavir and, to a lesser extent,
didanosine were associated with an increased risk of MI. The
increased risk associated with recent exposure to abacavir was,
however, diminished [6], while at the same time, a slight in-
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creased risk associated with cumulative exposure to abacavir
was found. These changes may simply reflect chance findings,
because exposure to this drug has increased (both estimates
remain within the CIs previously reported). However, it may
be that increased exposure to the drug has allowed us to more
accurately capture the risk associated with cumulative exposure
to the drug, which was previously undetectable, or that rapid
changes in patient management have meant that some of those
at highest risk of an MI have already switched away from aba-
cavir to other drugs. Since the publication of our earlier findings
on this drug, several studies have presented data to support an
association between abacavir use and MI risk [28–30], whereas
others have presented data that does not support this associ-
ation [31, 32]. An explanation for the different findings of these
studies remains to be elucidated, although study design (ob-
servational vs experimental), patient inclusion criteria, con-
comitant use of PIs, and duration of follow-up may all play a
role.
There have been reports of associations between tenofovir
and several renal toxicities [33–35]. However, the drug is
thought to cause fewer lipid perturbations than do other NRTIs
[36, 37]. In the present analysis, neither cumulative nor recent
exposure to the drug was associated with an excess risk of MI,
although CIs remain wide, reflecting the relatively recent in-
troduction of this drug into routine use and hence the limited
total exposure time. There have been concerns that our findings
regarding abacavir exposure may simply reflect channeling bias,
whereby individuals at the highest risk of MI (as determined
through traditional CVD risk factors) may have been prefer-
entially treated with this drug. Although we have previously
provided arguments against this hypothesis [6], our experience
suggests that tenofovir has also tended to be used preferentially
in individuals with known higher CVD risk (and our present
analysis would suggest that the cardiovascular risk factors of
those exposed to tenofovir are not markedly different from the
risk factors of those exposed to abacavir). Thus, if for some
reason our analyses are unable to remove any bias that results
from channeling, then we would expect to see an (artifactual)
association between MI risk and tenofovir exposure similar to
the association found with abacavir exposure. Of note, recent
suggestions that the association between MI risk and abacavir
may be a consequence of channeling patients at risk of chronic
kidney disease (a risk factor for CVD) away from antiretroviral
drugs with known adverse effects (particularly tenofovir and
indinavir) do not appear to be supported in our study [38].
Individual drugs from the NNRTIs. We did not observe
any associations between the development of MI and recent or
cumulative exposure to either nevirapine or efavirenz, consis-
tent with previous findings on this drug class [5]. Although
efavirenz has been reported to cause elevated triglyceride levels
[13, 14, 39], these increases do not appear to translate into an
increased risk of clinical CVD. Recent studies have reported
that nevirapine is associated with increases in HDL [40, 41],
suggesting that the drug may have beneficial effects on cardio-
vascular risk. Of note, whereas the relative risk associated with
cumulative exposure to nevirapine was !1, suggesting a possible
cardioprotective role, this association was not strong and was
not statistically significant ( ).Pp .34
Limitations. We did not formally adjust P values to take
account of the multiple tests performed. This is in line with
many other analyses of cohort studies in which the value of
such adjustments is debated [42, 43]. We have focused our
attention only on associations that are robust in sensitivity
analyses and highly significant, which suggests that they are
unlikely to be chance findings. As with any observational study,
our findings cannot be assumed to reflect causal associations
and must be interpreted cautiously because of the potential for
unmeasured confounding. Although an optimal study design
would require the use of a randomized trial, the large sample
size and follow-up required for such a trial renders it unlikely
to be feasible. HIV treatment patterns are complex [44], and
any analysis of treatment exposure in an observational study
will always reflect a simplification of a more complex reality.
Finally, our findings suggest that, within the PI drug class, some
PIs (ie, indinavir and lopinavir-ritonavir) are associated with a
stronger MI risk than are others. Although an approximate test
of heterogeneity suggested some evidence that the different
drugs within the PI class do have different propensity to cause
MI, the P value from this test was only marginally significant
( ), and the CIs for the individual estimates do overlap.Pp .02
Thus, additional follow-up will allow us to more fully explore
possible differences between drugs within the PI class.
In summary, we examined the risk of MI associated with
exposure to individual antiretroviral drugs from 3 major drug
classes in this large prospective cohort study. Of the individual
drugs examined, indinavir, lopinavir-ritonavir, abacavir, and
didanosine were all associated with an increased risk of MI.
This risk appeared to increase with cumulative exposure to the
2 PIs and could partly be explained by the dyslipidemia caused
by these drugs. In contrast, associations between MI risk and
abacavir and didanosine exposure were largely confined to those
patients with recent exposure to the drugs and did not appear
to be driven by dyslipidemia. The overall rate of MI remains
relatively low in this study, and any toxicities of antiretroviral
drugs must always be interpreted in the context of the benefits
that these drugs provide, but our findings do highlight the need
for studies to continue to examine the complications associated
with specific antiretroviral drugs.
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Bartsch, W. M. El-Sadr, E. Krum, G. Thompson, and D. Went-
worth. Participating physicians: R. Luskin-Hawk (Chicago, Il-
linois); E. Telzak (Bronx, New York); W. M. El-Sadr (Harlem,
New York); D. I. Abrams (San Francisco, California); D. Cohn
(Denver, Colorado); N. Markowitz and L. R. Crane (Detroit,
Michigan); R. Arduino (Houston, Texas); D. Mushatt (New
Orleans, Louisiana); G. Friedland (New Haven, Connecticut);
G. Perez (Newark, New Jersey); E. Tedaldi (Philadelphia, Penn-
sylvania); E. Fisher (Richmond, Virginia); F. Gordin (Wash-
ington, DC); J. Sampson (Portland, Oregon); and J. Baxter
(Camden, New Jersey).
EuroSIDA (multinational). Central coordination: O. Kirk,
A. Mocroft, M. Ellefson, A. N. Phillips, and J. D. Lundgren.
Participating countries and physicians: Argentina: M. Losso
(national coordinator) and C. Elias. Austria: N. Vetter (national
coordinator) and R. Zangerle (national coordinator). Belarus:
I. Karpov (national coordinator), A. Vassilenko, V. M. Mitsura,
and O. Suetnov. Belgium: N. Clumeck (national coordinator),
L. Vandekerckhove (national coordinator), S. De Wit, B. Poll,
and R. Colebunders. Bosnia: V. Hadziosmanovic (national co-
ordinator). Bulgaria: K. Kostov (national coordinator). Croatia:
I. Begovac (national coordinator). Czech Republic: L. Machala
(national coordinator), H. Rozsypal, and D. Sedlacek. Den-
mark: J. Nielsen (national coordinator), G. Kronborg, T. Ben-
field, M. Larsen, J. Gerstoft, T. Katzenstein, A.-B. E. Hansen,
P. Skinhøj, C. Pedersen, and L. Oestergaard. Estonia: K. Zilmer
(national coordinator) and J. Smidt. Finland: M. Ristola (na-
tional coordinator). France: C. Katlama (national coordinator),
J.-P. Viard, P.-M. Girard, J. M. Livrozet, P. Vanhems, C. Pradier,
F. Dabis, and D. Neau. Germany: J. Rockstroh (national co-
ordinator), R. Schmidt, J. van Lunzen, O. Degen, H. J. Stell-
brink, S. Staszewski, J. Bogner, and G. Fa¨tkenheuer. Greece: J.
Kosmidis (national coordinator), P. Gargalianos, G. Xylomenos,
J. Perdios, G. Panos, A. Filandras, E. Karabatsaki, and H. Sam-
batakou. Hungary: D. Banhegyi (national coordinator). Ireland:
F. Mulcahy (national coordinator). Israel: I. Yust (national co-
ordinator), D. Turner, M. Burke, S. Pollack, G. Hassoun, and
S. Maayan. Italy: A. Chiesi (national coordinator), R. Esposito,
I. Mazeu, C. Mussini, C. Arici, O. Riuniti, R. Bergamo, F. Pris-
tera, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, A. Chi-
rianni, E. Montesarchio, M. Gargiulo, G. Antonucci, F. Iacomi,
P. Narciso, C. Vlassi, M. Zaccarelli, A. Lazzarin, R. Finazzi, M.
Galli, A. Ridolfo, and A. d’Arminio Monforte. Latvia: B. Roz-
entale (national coordinator) and P. Aldins. Lithuania: S. Chap-
linskas (national coordinator). Luxembourg: R. Hemmer (na-
tional coordinator) and T. Staub. Netherlands: P. Reiss (national
coordinator). Norway: J. Bruun (national coordinator), A.
Maeland, and V. Ormaasen. Poland: B. Knysz (national coor-
dinator), E. Jablonowska (national coordinator), J. Gasio-
rowski, A. Horban, E. Bakowska, D. Prokopowicz, R. Flisiak,
A. Boron-Kaczmarska, M. Pynka, M. Beniowski, E. Mularska,
H. Trocha, E. Malolepsza, and K. Wojcik. Portugal: F. Antunes
(national coordinator), E. Valadas, K. Mansinho, and F. Maltez.
Romania: D. Duiculescu (national coordinator). Russia: A.
Rakhmanova (national coordinator), E. Vinogradova, and S.
Buzunova. Serbia: D. Jevtovic (national coordinator). Slovakia:
M. Mokra´sˇ (national coordinator) and D. Stanekova´. Slovenia:
J. Tomazic (national coordinator). Spain: J. Gonza´lez-Lahoz
(national coordinator), S. Moreno (national coordinator), V.
Soriano, L. Martin-Carbonero, P. Labarga, B. Clotet, A. Jou, R.
Paredes, C. Tural, J. Puig, I. Bravo, J. M. Gatell, J. M. Miro´, P.
Domingo, M. Gutierrez, G. Mateo, and M. A. Sambeat. Sweden:
A. Karlsson (national coordinator), P. O. Persson, and L. Flam-
holc. Switzerland: B. Ledergerber (national coordinator), R.
Weber, P. Francioli, M. Cavassini, B. Hirschel, E. Boffi, H. Fur-
rer, M. Battegay, and L. Elzi. Ukraine: E. Kravchenko (national
coordinator), G. Kutsyna (national coordinator), S. Servitskiy
(national coordinator), S. Antoniak (national coordinator), M.
Krasnov (national coordinator) and N. Chentsova. United
Kingdom: S. Barton (national coordinator), A. M. Johnson, D.
Mercey, A. Phillips, M. A. Johnson, A. Mocroft, M. Murphy,
J. Weber, G. Scullard, M. Fisher, and C. Leen.
HivBivus (Sweden). Central coordination: L. Morfeldt, G.
Thulin, and A. Sundstro¨m. Participating physicians: B. A˚ker-
lund (Huddinge); K. Koppel and A. Karlsson (Stockholm); and
L. Flamholc and C. Ha˚kanga˚rd (Malmo¨).
Italian Cohort Naive to Antiretrovirals (ICONA) Foun-
dation (Italy). Governing body: M. Moroni (Chair), G. Ca-
rosi, R. Cauda, F. Chiodo, A. d’Arminio Monforte, G. Di Perri,
M. Galli, R. Iardino, G. Ippolito, A. Lazzarin, F. Mazzotta, R.
Panebianco, G. Pastore, and C.F. Perno. Scientific secretary: A.
d’Arminio Monforte. Steering committee: A. Ammassari, A.
Antinori, C. Balotta, P. Bonfanti, M. R. Capobianchi, A. Cas-
tagna, F. Ceccherini-Silberstein, A. Cozzi-Lepri, A. d’Arminio
Monforte, A. De Luca, C. Gervasoni, E. Girardi, S. Lo Caputo,
F. Maggiolo, R. Murri, C. Mussini, M. Puoti, and C. Torti.
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Statistical and monitoring team: A. Cozzi-Lepri, I. Fanti, T.
Formenti, and M. Prosperi. Participating physicians: M. Mon-
troni, A. Giacometti, A. Costantini, and A. Riva (Ancona); U.
Tirelli and F. Martellotta (Aviano-PN); G. Pastore and N. Ladisa
(Bari); F. Suter and F. Maggiolo (Bergamo); F. Chiodo, G. Ver-
ucchi, and C. Fiorini (Bologna); G. Carosi, G. Cristini, C. Torti,
C. Minardi, and D. Bertelli (Brescia); T. Quirino and C. Abeli
(Busto Arsizio); P. E. Manconi and P. Piano (Cagliari); J. Vec-
chiet and M. Farenga (Chieti); G. Carnevale and S. Lorenzotti
(Cremona); F. Ghinelli and L. Sighinolfi (Ferrara); F. Leoncini,
F. Mazzotta, M. Pozzi, and S. Lo Caputo (Firenze); G. Pagano,
G. Cassola, G. Viscoli, A. Alessandrini, and R. Piscopo (Gen-
ova); F. Soscia and L. Tacconi (Latina); A. Orani and R. Rossotto
(Lecco); D. Tommasi and P. Congedo (Lecce); A. Chiodera and
P. Castelli (Macerata); M. Galli, A. Lazzarin, G. Rizzardini, I.
Schlacht, A. d’Arminio Monforte, A. L. Ridolfo, A. Foschi, A.
Castagna, S. Salpietro, S. Merli, S. Melzi, M. C. Moioli, P. Cic-
coni, and T. Formenti (Milano); R. Esposito and C. Mussini
(Modena); A. Gori (Monza), N. Abrescia, A. Chirianni, C. M.
Izzo, M. De Marco, R. Viglietti, and E. Manzillo (Napoli); C.
Ferrari and P. Pizzaferri (Parma); F. Baldelli and G. Camanni
(Perugia); G. Magnani and M. A. Ursitti (Reggio Emilia); M.
Arlotti and P. Ortolani (Rimini); R. Cauda, M. Andreoni, A.
Antinori, G. Antonucci, P. Narciso, V. Tozzi, V. Vullo, A. De
Luca, M. Zaccarelli, R. Acinapura, P. De Longis, M. P. Trotta,
M. Lichtner, and F. Carletti (Roma); M. S. Mura and G. Ma-
deddu (Sassari); P. Caramello, G. Di Perri, and G. C. Orofino
(Torino); E. Raise and F. Ebo (Venezia); and G. Pellizzer and
D. Buonfrate (Vicenza).
Nice HIV Cohort (France). Central coordination: C. Pra-
dier, E. Fontas, and C. Caissotti. Participating physicians: P.
Dellamonica, L. Bentz, E. Bernard, E. Cua, F. De Salvador-
Guillouet, J. Durant, R. Farhad, S. Ferrando, V. Mondain-Mi-
ton, I. Perbost, B. Prouvost-Keller, P. Pugliese, V. Rahelinirina,
P. M. Roger, and M. Vassallo. Clinical research assistant: E.
Bae¨z.
Swiss HIV Cohort Study (SHCS; Switzerland). P. Francioli
(President), M. Battegay, E. Bernasconi, J. Bo¨ni, H. Bucher, P.
Bu¨rgisser, S. Cattacin, M. Cavassini, R. Dubs, M. Egger, L. Elzi,
P. Erb, M. Fischer, M. Flepp, A. Fontana, H. J. Furrer, M.
Gorgievski, H. Gu¨nthard, B. Hirschel, L. Kaiser, C. Kind, T.
Klimkait, U. Lauper, B. Ledergerber, M. Opravil, F. Paccaud,
G. Pantaleo, L. Perrin, J.-C. Piffaretti, M. Rickenbach, C. Rudin
P. Schmid, J. Schu¨pbach, R. Speck, A. Telenti, A. Trkola, P.
Vernazza, R. Weber, and S. Yerly.
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